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An integrated clinical program and crowdsourcing strategy for
genomic sequencing and Mendelian disease gene discovery
Alireza Haghighi1,2,3,4,5, Joel B. Krier1, Agnes Toth-Petroczy1, Christopher A. Cassa1,5, Natasha Y. Frank1,5, Nikkola Carmichael1,
Elizabeth Fieg1, Andrew Bjonnes1, Anwoy Mohanty1, Lauren C. Briere6, Sharyn Lincoln7, Stephanie Lucia7, Vandana A. Gupta1,
Onuralp Söylemez1, Sheila Sutti1, Kameron Kooshesh1, Haiyan Qiu1, Christopher J. Fay1, Victoria Perroni1, Jamie Valerius1,
Meredith Hanna1, Alexander Frank1, Jodie Ouahed8, Scott B. Snapper8,9, Angeliki Pantazi1, Sameer S. Chopra10, Ignaty Leshchiner5,
Nathan O. Stitziel11, Anna Feldweg12, Michael Mannstadt13, Joseph Loscalzo12, David A. Sweetser6, Eric Liao14, Joan M. Stoler7,
Catherine B. Nowak7,15, Pedro A. Sanchez-Lara16, Ophir D. Klein 17, Hazel Perry17, Nikolaos A. Patsopoulos1,5,18,
Soumya Raychaudhuri1,5,19,20, Wolfram Goessling1,5,9,10, Robert C. Green1,5, Christine E. Seidman2,3,4,5, Calum A. MacRae1,2,5,
Shamil R. Sunyaev 1,5, Richard L. Maas1 and
Dana Vuzman1,2,5 Undiagnosed Diseases Network, Brigham and Women’s Hospital FaceBase Project, Brigham Genomic Medicine
(BGM)
Despite major progress in defining the genetic basis of Mendelian disorders, the molecular etiology of many cases remains
unknown. Patients with these undiagnosed disorders often have complex presentations and require treatment by multiple health
care specialists. Here, we describe an integrated clinical diagnostic and research program using whole-exome and whole-genome
sequencing (WES/WGS) for Mendelian disease gene discovery. This program employs specific case ascertainment parameters, a
WES/WGS computational analysis pipeline that is optimized for Mendelian disease gene discovery with variant callers tuned to
specific inheritance modes, an interdisciplinary crowdsourcing strategy for genomic sequence analysis, matchmaking for additional
cases, and integration of the findings regarding gene causality with the clinical management plan. The interdisciplinary gene
discovery team includes clinical, computational, and experimental biomedical specialists who interact to identify the genetic
etiology of the disease, and when so warranted, to devise improved or novel treatments for affected patients. This program
effectively integrates the clinical and research missions of an academic medical center and affords both diagnostic and therapeutic
options for patients suffering from genetic disease. It may therefore be germane to other academic medical institutions engaged in
implementing genomic medicine programs.
npj Genomic Medicine  (2018) 3:21 ; doi:10.1038/s41525-018-0060-9
INTRODUCTION
Although rare as unique disease entities, Mendelian disorders are
altogether more frequent than previously thought and collectively
affect millions of patients worldwide.1 Often life-threatening or
chronically debilitating, Mendelian diseases are estimated to
account for 12 and 2% of pediatric and adult hospital admissions,
respectively.2 Early molecular diagnosis and individualized man-
agement that targets the underlying pathophysiology can
improve the quality of life for many of these patients. There are
approximately 7,000 clinically described rare Mendelian diseases,
and only about half of these have a clearly described genetic
cause.2 The total number of Mendelian diseases may be
substantially higher,3 leaving many new conditions to be clinically
described. In addition, the benefits of genomic sequencing in
Mendelian diseases extend beyond individuals with rare disorders.
Genes responsible for large effects in Mendelian disorders may
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contribute moderate effects to more common forms of the same
or related disease phenotypes.4–6
PROGRAM OVERVIEW
We describe a multidisciplinary integrated clinical diagnostic
program situated in an academic medical center whose goal is to
identify the genetic basis of presumptive undiagnosed Mendelian
conditions. This differs from typical clinical diagnostic services,
which primarily test for genetic variants whose association with
clinical disorders is often supported by substantial prior evidence.
The central premise that informs this multidisciplinary integrated
model is that a particular subset of clinical genetics cases that are
encountered in the hospital and outpatient setting offer unique
opportunities for gene discovery and disease pathway elucidation
and, in some cases, for the re-purposing of existing therapeutics or
the advent of novel therapeutic and clinical management options
(Fig. 1).
At the present, several national sequencing projects aim to
establish platforms for genomic epidemiology that include a
health database and biobank. Most notably, these include the US
“All of Us” Research Program (https://allofus.nih.gov), the Million
Veterans Program (MVP) (https://www.research.va.gov/mvp/), the
UK 100,000 Genomes Project (https://www.genomicsengland.co.
uk), The Genome of the Netherlands,7 and Korean Genome and
Epidemiology Study (KoGES).8 In addition, several smaller pro-
grams with a more precise focus on monogenic diseases, such as
the National Institutes of Health (NIH) Undiagnosed Diseases
Network (UDN),9 the Idiopathic Diseases of Man (IDIOM) study,10
the Centers for Mendelian Genomics (CMG),11,12 and the UK
Deciphering Developmental Disorders (DDD),13 feature the
application of genome sequencing integrated with clinical
assessment and multidisciplinary gene discovery.
Here, we describe a multidisciplinary integrative clinical and
research program called Brigham Genomic Medicine (BGM) for
patients presenting with a wide range of phenotypic traits and
family history consistent with a Mendelian pattern of inheritance.
A distinctive feature of BGM is its focus on undiagnosed
monogenic disease cases that are refractory to standard
diagnostic approaches. In addition, the program provides an
integrated and continuous pathway from case ascertainment to
treatment. Whenever reasonable, a new or improved manage-
ment strategy is initiated for the patients based on novel genomic
findings.
The main objectives of the program described here are to: (1)
use state-of-the-art clinical and research methods to discover the
genetic causes of undiagnosed Mendelian cases; (2) provide new
diagnostic and treatment options for these patients; and (3)
promote the clinical implementation of genomic medicine by
educating physicians and researchers to recognize possible
genetic disorders. An important feature of this program and its
accompanying team is its interdisciplinary nature. For example, in
addition to academic physicians from different clinical specialties
and subspecialties, the program includes clinical molecular
geneticists, genetic counselors, and scientists with expertise in
statistical genetics, genomic analysis, bioinformatics, molecular
genetics, and experimental disease modeling. The interdisciplinary
team is therefore well-equipped to tackle analytical and diagnostic
challenges as they arise.
The program team routinely includes about 25 members who
meet weekly to review 1–3 cases. Meetings are typically structured
around new case presentations or discussion of ongoing analyses
for existing cases. New cases are presented by referring physicians
with the goal of discussing the medical appropriateness of the
case, and the a priori likelihood of a tractable solution via whole-
exome and whole-genome sequencing (WES/WGS); a decision is
then made about each case’s acceptance to the program.
Decisions require a quorum of at least three clinicians and three
biomedical scientists. If a case is accepted for WES/WGS, the
patient and relevant family members are consented to BGM
research protocol, samples are sent to a commercial sequencing
provider, and the resulting BAM sequence files are analyzed
further in-house using a genomic sequence analysis pipeline, as
described below. The results of the in-house analysis pipeline are
then curated and compared to the “clinical genomic sequencing”
report, when available.
Once the variant list has been generated, the referring physician
and program team reconvene to discuss and refine the results.
These meetings are typically preceded by a distribution of the
case synopsis and variant list via a crowdsourcing portal, also
described below. To accommodate busy clinical work schedules,
referring physicians may participate either in person or via
conference call. To encourage the participation of clinical faculty
and physicians, the weekly case conference provides continuing
medical education (CME) credit to clinical participants.
CASE ASCERTAINMENT AND INFORMED CONSENT
To optimize the probability of solving a case, specific criteria are
used to select cases and to determine their suitability for WES or
WGS. These selection criteria include: (1) the likelihood of solving
the case, which in turn is a function of the likelihood that a
phenotype has an underlying monogenic etiology, the predicted
inheritance mode, and the availability of the family members
needed to solve the case; (2) the disease morbidity that might be
alleviated if the case were solved; (3) the potential for scientific
discovery (i.e., if we suspect a novel pathway is involved, we are
more inclined to accept the case); and (4) the potential relevance
of the case to more common diseases with similar phenotypes.
Clinicians from all clinical departments are encouraged to refer
Mendelian cases that could have broad impact on patient care if
the causal gene were identified. To date, physician champions in
the departments of genetics, pediatrics newborn medicine,
gastroenterology, cardiology, rheumatology, endocrinology,
nephrology, dermatology, and hematology as well as the NIH
UDN, and the National Institute of Dental and Craniofacial
Research (NIDCR) FaceBase Consortium have referred most of
the cases to the program. However, since the ultimate impact of
solving a case cannot be determined in advance, all cases
involving medically significant disease are potentially eligible for
consideration. A genetic counselor and a clinical geneticist
examine the referred patients and review all available medical
records and the family history. Patients who appear to be good
candidates for WES or WGS have their cases presented by their
referring physician to the program, as described above, to
determine whether they meet the inclusion criteria and to define
the optimal testing strategy; for example, whether to use WES,
WGS, or some intermediate approach such as chromosomal
microarray. WES is ordinarily the default sequencing strategy,
primarily for cost considerations, but factors favoring WGS include:
(1) cases in which a chromosomal rearrangement, insertion or
deletion, or copy number variation is suspected; (2) cases in which
uniform genome coverage is preferred; and (3) cases in which a
regulatory variant is assumed due to high suspicion of a specific
monogenic etiology despite a negative WES. The cases selected
for WES/WGS are described using Human Phenotype Ontology
(HPO), which provides a structured, comprehensive set of
terms for the phenotypic abnormalities characterizing human
disease.14–16
Unlike many other similar programs that may accept undiag-
nosed cases at large, the cases selected for WES/WGS analysis via
this program are unique in that in general they are not routinely
solvable by conventional WES of the proband alone or by
application of conventional clinical or commercial WES analytical
pipelines. Thus, patients and family members undergo an
informed consent process to participate in a research study and
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to have their data shared for a crowdsourcing analysis in
accordance with an institutional review board (IRB)-approved
protocol. To protect privacy, each patient is assigned an
anonymous identification number at admission.
GENOMIC SEQUENCING AND DATA ANALYSIS
Blood is drawn and DNA is extracted for WGS, or a combination of
WES (to detect coding variants) and single-nucleotide polymorph-
ism chromosomal microarrays to detect structural and copy
number variants, and to conduct genome-wide linkage analysis if
necessary. Sequencing is performed in a CLIA (Clinical Laboratory
Improvement Amendments)-certified laboratory when clinical
indications for sequencing exist and once reimbursement by
insurers is approved; otherwise, sequencing is conducted in a
research laboratory.
Our preferred sequencing and analytical approach utilizes
specific inheritance models for each case in addition to the
following assumptions to identify a small list of candidate variants
without bias from known biological or phenotypic gene associa-
tions: (1) rare, severe, monogenic disease is typically caused by
coding variants that are absent or extremely rare in the general
population; (2) rare, severe monogenic diseases are caused by
highly penetrant genetic variants. For example, in cases with only
a single affected family member for which dominant de novo and
recessive inheritance modes are each possible, our preferred
approach is to sequence the trio consisting of proband and both
parents and to analyze the proband’s variants with respect to the
parental genotypes. In such a case, we expect to identify 1–2 de
novo variants, 0–1 homozygous variants, and 2–5 compound
heterozygous variants at allele frequencies lower than 0.1% in the
population. In consanguineous recessive cases and/or recessive
cases with available affected siblings, the DNA of the proband can
be sequenced along with that of an affected sibling, and the
shared recessive variants can then be further tested for appro-
priate segregation among unaffected siblings by simple PCR
analysis or Sanger sequencing. In dominant cases with multiple
affected family members, we prefer to sequence the proband in
parallel with the most remote affected available relative, most
commonly a cousin, to reduce the number of candidate variants
to the smallest number possible, ideally less than 10. Finally,
individual cases without available relatives or cases where the
phenotype requires both a discrete environmental stimulus and a
genetic susceptibility variant can occasionally be solved from a
single genome sequence.
The two major components of the analytical pipeline include:
(1) alignment and calling of sequence variants from WES/WGS
data, and (2) interpretation of the functional consequences of the
identified sequence variants (Fig. 2a). This pipeline includes
algorithms that improve the sensitivity and specificity of
Mendelian calling using probabilistic models that capitalize on
data related to the mode of inheritance, and tools to identify non-
coding regulatory variants in WGS data (Fig. 2b). One of the
distinguishing features of our WES/WGS computational analysis
pipeline is its optimization for Mendelian gene discovery with
callers tuned to specific inheritance modes (e.g., de novo
dominant, shared dominant, or other inheritance modes). This
innovation substantially reduces the number of candidate variants
that require confirmatory Sanger sequencing at additional time
and cost. These callers are optimized for high specificity and
sensitivity by using familial information and unrelated samples to
detect technical artifacts present in the sequencing and alignment
process. These callers also extend the power of joint calling by
gauging the presence of technical artifacts along with estimation
of the prevalence of an allele at any variant call location.
Independent Sanger sequencing has confirmed the high accuracy
of these callers (Mohanty et al., submitted). The unified Bayesian
framework they employ enables the best decision about whether
an allele is present or if alternate reads are present at the location
as a technical artifact. Downstream analysis calculates the
statistical probability of detecting each variant by chance based
on a constraint missense Z score, and the probability of being loss-
of-function intolerant (pLI)17 (Fig. 2c). In addition, we use
Phenomizer,18,19 a diagnostics tool that uses semantic similarity
metrics to measure phenotypic similarity between queries and
hereditary diseases annotated with the use of the HPO. BGM also
uses this pipeline to analyze cases from the National Human
Genome Research Institute (NHGRI) UDN9 and from the NIDCR
FaceBase Consortium.20,21
Putative causal variants must fulfill the following criteria: (1) co-
segregation with the disease based on the inheritance mode; (2)
rare with a minor allele frequency of 0.1% or less in all populations
from unaffected consortia (e.g., gnomAD (genome Aggregation
Database) and (3) predicted functional impact on the gene product.
CAUSALITY OF CANDIDATE GENES
To establish the causality of variants identified by WES/WGS for a
given case, appropriate follow-up studies are tailored to address
the relevance of the gene and genetic variant to the disease
phenotype in question, in collaboration with faculty across the
academic medical center. This approach makes use of a flexible
two-part strategy: (1) identifying additional cases (e.g., two or
more independent cases) with a similar phenotype bearing
presumptive functional variants in the same gene, typically via
Matchmaker Exchange;22 and (2) empiric functional experiments.
For the latter, we use a wide range of experimental systems for
biological validation of the top 1–3 identified candidate genes,
Clinical 
workup
Biobanking
WGS/WES
Variant 
analysis
General Workflow
Validation/
Segregation
Match-
making
Functional
validation
Clinical
application
Relevance 
to common 
conditions
Crowd-
sourcing 
Fig. 1 Workflow overview. The workflow begins with the clinical
assessment of cases, where referring physicians present cases of
presumptive unknown monogenic etiology from their clinical
practice for the collective development of a case solution strategy.
Based on the inferred inheritance mode, the most informative family
members are selected for genomic sequencing followed by analysis
of the WES/WGS data using a computational pipeline designed to
identify rare Mendelian variants. A final candidate gene list is
prioritized using in-house bioinformatic tools, literature surveys, and
crowdsourcing. The final candidate gene is confirmed by segrega-
tion analysis, matchmaking for second case hits, and by in vitro and
in vivo functional studies. Both genomics and functional biology
thus inform the diagnosis and clinical management of individual
patients, while unique patient conditions provide insight into gene
and pathway function
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including: (a) in vitro protein and biochemical assays to study the
interactive and enzymatic effects of specific variants on protein
function; (b) use of cellular models, including human induced
pluripotent stem cells and CRISPR (Clustered Regularly Interspaced
Short Palindromic Repeats) to investigate the effects of gene
inactivation or specific variants on cellular function; and (c) use of
engineered zebrafish and mouse models to recapitulate human
phenotypes.
As an example (Table 1, case 7), we identified distinct PIEZO2
variants (p.Glu2727del and p.Ile802Phe) in two separate patients
with the musculoskeletal contracture and respiratory disease
Distal Arthrogryposis type 5 (DA5).23 One of the patients
presented to our emergency department in acute respiratory
distress during flu season. Electrophysiological studies performed
with a collaborator demonstrated that the identified PIEZO2
variants affect biophysical properties related to channel inactiva-
tion and caused PIEZO2-dependent, mechanically activated
currents to recover faster from inactivation, resulting in increased
channel activity in response to a mechanical stimulus. These
findings indicated that DA5 is caused by gain-of-function variants
in PIEZO2.
In sum, we pursue biological validation through collaboration
with investigators with expertise in functional assays relevant to
the discovered genes. Thus, whenever required, we seek to
establish collaborations with scientists external or internal to our
institution, whose expertise focuses on the gene or disease of
interest.
CROWDSOURCING AND MATCHMAKER ANALYSES
Solving undiagnosed and complex cases requires diverse knowl-
edge and expertise. While many cases benefit from analysis via a
“case champion” model in which one individual, usually with
special knowledge of the disease or of a primary candidate gene,
drives the analysis, this strategy is not always available or
successful. To further help solve challenging cases we have
implemented an innovative crowdsourcing strategy among
faculty and staff to utilize specialized expertise across the entire
academic medical center. Our crowdsourcing system is restricted
to physicians, clinical staff, and research faculty of the parent
institution. All cases are fully de-identified, allowing useful
information to be shared without violating HIPAA (Health
Insurance Portability and Accountability Act) regulations or patient
privacy. The HIPAA-compliant portal is securely installed behind a
firewall and integrated with the institution’s authentication system
(i.e., username and password) to provide controlled access.
The patient data shared for crowdsourcing include de-identified
clinical and laboratory details as well as a list of variants identified
by WES/WGS (Fig. 3). Together with BGM faculty and collaborators,
the main bioinformatic analyst for each case reviews the variant
and clinical data and organizes the analysis and presentation of
the case. In addition, other scientists and clinicians throughout the
institution can request to participate in the crowdsourcing
analysis. These participating analysts work collaboratively or
independently on cases within a timeframe specified by the
program director, but with a degree of flexibility that encourages
participation. In addition, there is no minimum time commitment
for participation in the crowdsourcing analyses, and participating
analysts spend from one to several hours a week. Once the
analyses are codified, the main analyst summarizes the various
analytical inputs and presents the case at the weekly program
meeting to all program staff including those who participated in
the crowdsourcing analysis. The interdisciplinary program team
discusses the findings and decides on the next steps. This
crowdsourcing innovation helps identify candidates and effective
validation assays that otherwise would have been missed,
engages the collective expertise of a broad range of faculty in
the exercise of analyzing Mendelian disease cases, and also serves
a broad educational purpose.
Our first 30 solved cases span a wide range of disorders
presenting in children and adults and were drawn from multiple
referral sources (Table 1). Criteria for establishing causality include:
(1) the existence of multiple independent cases with similar
phenotypes and variants in the same gene; (2) recapitulation of
the human disease phenotype, in whole or in part, in an
appropriate animal model, typically mouse or zebrafish; and (3)
demonstration of a molecular defect in an appropriate cellular or
biochemical assay.
Seventeen of the cases were solved using the crowdsourcing
mechanism among ~50 participating faculty, scientists, physicians,
genetic counselors, and fellows in our institution, while the
remaining cases employed a case champion model. For example,
one illustrative case that was resolved via the crowdsourcing
mechanism involved a male infant with symptoms consistent with
very early-onset inflammatory bowel disease (VEO-IBD) and
hearing loss (Ouahed, Snapper et al. manuscript in preparation).
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Fig. 2 Overview of the analytical pipeline. a The computational pipeline is shown, including discrete steps for the alignment of read data,
joint genotyping, variant prioritization programs, incorporation of external data sources, and variant visualization, culminating in downstream
analyses; b detailed breakdown of the upstream analysis is shown, including the production of validated, annotated, and prioritized candidate
variants; c detailed breakdown of the downstream analysis culminates in the evaluation of candidate genes and the variants within them for
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The patient’s clinical and genomic data were posted on the
program portal. A genetic counselor annotated the potential
relevance of a novel gene variant with the comment that:
“Variants in a homologous gene are associated with variable
clinical presentations in patients with familial hemophagocytic
lymphohistiocytosis (HLH) type 5 - sensorineural hearing deficit,
abnormal bleeding, and, most frequently, severe diarrhea only
present in early-onset disease infantile IBD and hearing loss.” In
this instance, the annotation for the homologous gene
provided an important clue that the variant was likely to be
causal in the VEO-IBD case. The significance of this variant was
subsequently confirmed by the identification of seven addi-
tional VEO-IBD cases that involve loss-of-function variants in the
same gene, and by accompanying functional studies (Ouahed
et al. manuscript in preparation).
The identification of additional unrelated patients with
overlapping phenotypes and deleterious intragenic variants in
the same gene constitutes a powerful strategy to establish the
causality of a given candidate disease gene of uncertain clinical
significance.23 To ascertain additional cases, we make extensive
use of Matchmaker Exchange,21 as well as of ad hoc inquiries to
other investigators who are actively working on phenotypically
related conditions. In the case of the patient with VEO-IBD and
bilateral hearing loss described above, additional unrelated
cases with deleterious variants in the same gene were
identified using Matchmaker Exchange and inquiries to
external investigators including the VEO-IBD consortium
(www.veoibd.org). Indeed, in this specific case, engagement
across multiple institutions resulted in a fruitful collaboration
with BGM. This work ultimately led to a novel disease gene
discovery and diagnosis for multiple families (Ouahed, Snapper
et al. manuscript in preparation).
In a second illustrative example (Table 1, case 5), the proband
in the case presented to an emergency room with painful,
dusky ischemic toes of uncertain etiology 3 days after the onset
of a mild upper respiratory infection. Despite extensive
diagnostic testing, consultants in rheumatology, vascular
medicine, cardiology, and nephrology could not establish a
diagnosis. The patient was therefore managed with a cocktail of
drugs including glucocorticoids, calcium channel blockers, and
anti-coagulants, and eventually recovered over many weeks. An
astute clinician determined that other family members had
presented with a range of similar findings (also in the setting of
presumed infection), which in the most extreme case required
amputation of affected digits. The family history was consistent
with an autosomal dominant mode of inheritance, and WGS
was used to analyze DNA both from the proband and an
affected cousin. The genomic analysis for these two individuals
identified 9 shared heterozygous variants and was posted on
the crowdsourcing portal. A developmental geneticist high-
lighted a missense variant in Complement Factor 3 (C3), which
alters a cleavage site required for production of C3 fragments
that act to restrain excessive complement activation. Based on
identification of a putative causative variant, follow-up testing
of the proband revealed baseline elevated serum complement
levels. While atypical hemolytic uremic syndrome (aHUS) was
clinically ruled out in part due to the absence of acute renal
failure, multiple family members carrying the familial C3 variant
were subsequently found to exhibit microscopic hematuria. We
posit that an infectious trigger for complement activation,
superimposed upon a C3 variant that disrupts normal comple-
ment inactivation, contributes to vascular damage in this
family. Given the suspected pathophysiology of the disorder,
we propose that the C5 inhibitor Eculizumab, which is already
clinically approved for the treatment of paroxysmal nocturnal
hemoglobinuria and aHUS, should be discussed as a possible
therapy during future episodes in affected family members.
Thus, this case illustrates how an environmental trigger, notablyT
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infection, can interact with a specific genetic variant to cause
disease. It also illustrates how identification of the causative gene
may suggest therapeutic approaches that are otherwise not be
considered in the care of affected family members.
In some cases, collaborators may also serve as matchmakers, by
introducing additional related but independent cases. For
example, in our investigation of the case of DA5 that involved
musculoskeletal contractures and severe restrictive lung disease,
an experimental collaborator whom we had contacted connected
us with Norwegian clinicians who had identified a second
intragenic variant in the PIEZO2 gene in an independent case,
thus establishing causality. This led to a multi-institutional
discovery of PIEZO2 as the cause of DA5.23
REPORTING EVIDENCE TO REFERRING CLINICIANS
When sufficient evidence supports a causal relationship between a
genetic variant and a disease phenotype, our group discusses the
results with the patient’s referring physician and other pertinent
clinical consultants in the context of the regular weekly meeting.
For cases in which empiric management previously provided little
benefit, additional therapeutic interventions may also be dis-
cussed. A comprehensive written report of the findings and
potential treatments suggested by the genetic mechanism is
submitted to the referring physician. Variants identified in
research-based analyses are independently confirmed in a CLIA
laboratory in accordance with return of results process defined in
our IRB-approved protocol. The referring physician invites the
patient and other relevant family members to visit the clinic for an
on-site discussion of the results and for counseling, typically with a
medical geneticist and/or a genetic counselor. This formal return
of results provides a satisfying culmination to the genomic
evaluation process, which is important since the overall process
for each case often takes many months. The turnaround time for
cases with novel gene discovery is 6 to 18 months, where the rate
limiting steps are (1) the experimental work required to elucidate
the function of the candidate gene (when it is unknown), and the
functional impact of the candidate variant; and (2) the identifica-
tion of independent cases with similar phenotypes caused by
variants in the same gene.
COMPLETED PROJECTS AND CLINICAL SIGNIFICANCE
The main distinction between BGM and other programs aimed at
clinical diagnosis of suspected monogenic disease is that our main
focus is on discovering novel disease–gene associations, most
typically in undiagnosed disease states. For this reason, cases with
recognizable or known phenotypes are either directed elsewhere
or are initially screened for the extant disease-causing variants
linked to those phenotypes. Therefore, the majority of cases that
come to the attention of the program described here are non-
routine, high-complexity cases, and often referred from other
programs, where they were deemed intractable.
To date, we have enrolled 244 families, sequenced DNA from
122 patients, along with additional samples from informative
family members, analyzed 106 of these cases (Supp. Table 1), and
elucidated a genetic etiology for 30 cases (Table 1). Another 48
cases (not listed here) have been resolved to the level of a
potentially pathologic variant in one or a very small number of
candidate genes, but require identification of additional related
cases or functional experiments to demonstrate causality. Of the
30 cases solved by our program and listed in Table 1, 6 were
referred to us with prior negative WES or gene panel sequencing,
while at least 10 of the solved cases, or one third, afforded a
genetic etiology for a previously unknown medical condition
(Table 1). In addition, several of the families that were solved by
this program had only one affected proband, and therefore
required a more complicated disease gene discovery analysis than
would otherwise be the case. Since our program’s primary focus is
on novel disease–gene discovery, and since cases for which a
known genetic variant is strongly suspected in advance of WES/
WGS are excluded from our pipeline, it is notable that our ~28%
(30/106) rate of gene identification is nominally equivalent to the
17–25% diagnostic yield reported by clinical genome sequencing
programs.24–28
Additional examples of significant disease-associated gene
identifications, summarized in Table 1, further illustrate specific
features of the program. These cases include PIEZO2 (a subtype of
distal arthrogryposis, a musculoskeletal contracture and respira-
tory disease),23 LOX (familial aortic dissection),29 WISP3 (precocious
arthritis),30 CHST11 (T cell lymphoma with limb abnormalities),31
complement factor C3 gene (Chopra et al., manuscript in
preparation), several cases of undiagnosed craniofacial dysmor-
phoses, and a gene that causes a rare form of lung cancer (Frank
et al., manuscript in preparation) among others.
Table 1 also depicts a ratio of 21 WES to 9 WGS cases under
“Sequencing strategy,” which is consistent with the ratio for all 122
patients, which includes 91 analyzed by WES and 43 by WGS. A
total of 251 samples were submitted for WES, or ~2.8 samples per
case, while 108 samples were submitted for WGS, or ~2.5 samples
per case. While the majority of solved cases identify non-
synonymous variants that should be captured by WES, the
advantages of WGS include more uniform coverage, precise
detection of regions of identity by descent, genome-wide data to
call structural variants, and the opportunity to call potential non-
coding regulatory variants within linkage disequilibrium peaks
around disease-associated genes. For example, in a case with
craniofacial anomalies and hypotonia we detected a translocation
that disrupts intron 2 of CAPZB (Table 1, case 12). Also, in a novel
syndrome of skeletal malformation and malignant lymphoproli-
ferative disease (Table 1, case 1), a partial deletion of CHST11 was
detected which might have been difficult to detect with WES
capture methodology. Finally, a progressive pseudorheumatoid
arthropathy of childhood (PPAC) case (Table 1, case 2) benefited
from careful detection of autozygous segments by WGS, which
reduced the analysis to only 6% of the genome given the
consanguineous family structure.
Some of our cases were diagnosed by identification of a novel
variant in a known disease-associated gene, despite our selection
Clinicians
Computational
Geneticists
Experimental
Biologists
Shared Clinical and Genetic Data (de-identified)
Gene-disease 
association
Variant 
pathogenicity
Additional 
cases
Clinical intervention
Experimental 
study design
Variant
analysis
Crowdsourcing Analysis
Disease Gene Discovery
Fig. 3 Crowdsourcing of Mendelian cases. Clinical and genomic
data of cases under analysis are presented in fully de-identified
format via a secure portal and in compliance with HIPAA and patient
privacy regulations. This crowdsourcing mechanism provides
clinicians, researchers, and data analysts with the opportunity to
“interactively” analyze the data, vet analytical approaches, explore
follow-up options, and to obtain second, third, or fourth opinions
before finalizing a particular analytical and validation strategy. In
some cases, the crowdsourcing strategy can serve as a matchmaker
for a second case based on the phenotype, genotype, or both
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criteria for gene discovery. Several reasons account for this
circumstance. First, some referred disorders are misdiagnosed or
undiagnosed simply because they are relatively rare and have not
been previously seen by the referring clinical team. An example of
such a case is PPAC, with a WISP3 variant (Table 1, case 2). Second,
some cases have had prior research grade WES and novel variants
in known genes have been missed by the referring research team
due to limitations of available WES interpretation tools. For
example, this was the case in infantile-onset IBD with a variant in
the disease-causing gene32,33 DOCK8 (Table 1, case 4). Lastly, some
patients have had WES or gene panels performed in clinical
laboratories that do not follow-up with functional studies on
reported variants of uncertain significance. This is illustrated by
the MED12 variant identified in a patient with congenital
anomalies, polydactyly, and developmental delay. Thus, WES/
WGS holds considerable value in rendering a definitive diagnosis
in undiagnosed genetic cases. Even if deep re-analysis does not
lead to the discovery of a novel disease-causing gene, clarification
of the etiology of atypical, ambiguous, or challenging cases often
expands our knowledge of the range of phenotypic states
associated with specific genes and provides a definitive diagnosis
for the patient and family.
In addition to providing insights into disease biology, the
identification of disease-causing genes has broader medical
ramifications. For example, once Mendelian disease-causing
variants are validated through functional studies, the role of these
genes in more common, related diseases states can be explored.
For example, a newly discovered gene for Mendelian IBD may
have immediate relevance to understanding the etiology of more
common adult forms of IBD, such as Crohn’s disease or ulcerative
colitis. As one approach to pursue such potential connections,
gene-centric PheWAS34,35 statistical analysis can be performed
across all phenotypic categories within available large-scale
sequencing datasets. Such analyses can validate specific Mende-
lian disease gene findings in the context of common disease, and
explore the broader value of the genetic information.
Other successful case analyses illustrate the potential of a
modern genomic medicine service to provide insight into disease-
causing pathways of direct therapeutic importance. For example, a
35-year-old Caucasian male presented to the hospital for
evaluation of a personal and family history of thoracic aortic
aneurysm and dissection (TAAD). He had undergone surgical
repair of pectus excavatum at 2 years of age and was diagnosed
with a large ascending aortic aneurysm at age 19. Based on these
anomalies and other physical features including tall stature, high
arched palate, and dental crowding, as well as a family history
consistent with an autosomal dominant mode of inheritance, he
was diagnosed of Marfan syndrome. However, genetic testing
identified no variants in FBN1, TGFBR1, and TGFBR2, the genes that
are associated with Marfan syndrome. Genetic testing performed
in the proband’s affected mother also failed to reveal any causal
variants in a larger collection of genes associated with connective
tissue disorders: ACTA2, COL3A1, MYH11, SLC2A10, SMAD3, or
MYLK. Therefore, WGS was performed for the proband and his
affected cousin and identified a p.Met298Arg missense variant in
the elastin and collagen cross-linking enzyme, Lysyl oxidase,
encoded by the LOX gene.29 This variant would place a repulsive
positive charge from Arg in the Cu2+ binding active site of the
enzyme. Lysyl oxidase activity in skin declines with low dietary Cu2
+ and increases with repletion.36 Taken together, these findings
suggest the hypothesis that Cu2+ supplementation, within US
Department of Agriculture (USDA) safety guidelines, might
augment the Cu2+-dependent enzymatic function of LOX and
therefore help protect against aortic disease in individuals carrying
this variant. This hypothesis is now directly testable in a murine
model where the specific genetic variant has been knocked-in to
the endogenous Lox locus. In addition, family members carrying
the p.Met298Arg variant are now being serially monitored by
echocardiography and by magnetic resonance angiography for
aortic dilatation, which may prevent significant morbidity and
mortality when identified early in the course of disease rather than
at the time of rupture.
CHALLENGES
Despite the successes mentioned above, programs for integrated
genomic medicine, such as that described here, face a number of
challenges. These include the time required to accumulate
evidence for disease causality of candidate genes and variants,
the development of a standardized clinical classification guideline
for variants of uncertain significance, gaining acceptance of
clinical reimbursement standards among third-party payers, and
assessing and reporting incidental findings. For example, in
addition to the 30 solved cases reported in Table 1, another 48
cases have been resolved to the level of single or few strong
candidate genes, but require further work to identify additional
phenotypically related cases with intragenic variants or to perform
the requisite functional experiments needed to establish causality.
Such experimental work, which has the potential to greatly
strengthen the genotype–phenotype correlation, is not currently a
reimbursable component of the clinical assessment. Thus, a
significant time lag in case resolution and a substantial funding
shortfall are to be expected in any genomic medicine program
that emphasizes new gene discovery in undiagnosed cases over
routine genetic diagnosis.
In addition, while the cost of clinical WES/WGS has dramatically
declined in recent years, the reimbursement policies of health
insurance companies and payers remain heavily biased to single
gene tests and gene panels. Though insurance companies are
starting to recognize the significant clinical utility of genomic
sequencing, initiatives such as ours have been funded by
institutional and extramural research sources. Ultimately, we
envision that the secondary analysis of genomic sequencing and
the integrated clinical practice of genomic medicine will be
supported by third-party payers. Currently, the research compo-
nents of such programs continue to depend upon institutional
and some targeted extramural support. Ultimately, the funding of
patient-level experimental biology may be reflected in the
reimbursement for clinical care, much as therapeutic drug trials
are currently cross funded by payers in oncology. To this end, we
plan to leverage the billing expertise of the Brigham and Women’s
Hospital Departments of Medicine (for professional billing) and
Pathology (for technical billing), while implementing the new
revenue streams available under the revised coding structure for
genetic testing. In January 2015, the American Medical Association
(AMA) released revised Current Procedural Terminology (CPT)
codes that reflect recent advances in genomic medicine, including
WES/WGS and the re-evaluation of existing sequence data for
both patients and family members.37 We have begun to prepare
to utilize these changes to CPT coding and billing to maximize the
clinical reimbursement for WES/WGS. Recognition of the clinical
utility of WES/WGS by clinical and translational research programs
will hopefully provide payers with a logical framework in which to
evaluate evidence for the value of genomic medicine to the health
care system.
CONCLUSION
Recent advances in genomic sequencing have enabled the
resolution of undiagnosed cases of human disease and can
provide answers to families and clinicians. The model described
here is based on well-defined genetic entry points into human
biology that lead to disease gene discovery, with both clinical
implications and subsequent mechanistic evaluation. This model
integrates state-of-the-art genetic research with innovation across
multiple domains, including a refined computational analysis
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pipeline, translatable functional assays, improved clinical pheno-
typing, and therapeutic intervention. As this program effectively
assimilates a multidisciplinary team of clinical and research
expertise in the task of diagnosing and treating these debilitating
conditions, this integrated monogenic disease gene discovery
model can be readily adapted by other academic medical centers.
Lastly, by promoting the clinical implementation of genomic
medicine, the genomic medicine program described here also
affords a unique educational opportunity for trainees and
investigators across many disciplines of biomedicine.
Data availability
Additional data supporting the findings of this study are available
within the supplementary information files. The genomic datasets
generated and/or analyzed during the current study are not
publicly available due to data and privacy protection considera-
tions but may be available on justified request.
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